Xeris to Participate in Upcoming Investor Conferences
-
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual)
- 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET
-
Leerink Global Healthcare Conference,
Miami, FL - 1x1 meetings and fireside chat on March 10, 2025 at 8:40 am ET
-
Barclays 27th Annual Global Healthcare Conference,
Miami, FL - 1x1 meetings only on March 11, 2025
Please check with each conference sponsor to arrange 1x1 meetings.
Webcast information for each fireside chat will be available at https://xerispharma.com/investor-relations.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205312553/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
